Home » Topics » Regulatory

Regulatory
RSS

Actemra approved in Japan for adult-onset Still's disease

May 23, 2019

FDA approves Venclexta with Gazyva for previously untreated CLL or SLL

May 16, 2019

FDA approves Bavencio with Inlyta for advanced renal cell carcinoma

May 15, 2019

FDA approves Eylea to treat all stages of diabetic retinopathy

May 14, 2019

FDA approves Cyramza for hepatocellular carcinoma previously treated with sorafenib

May 13, 2019

Waylivra receives conditional marketing authorization from the European Commission

May 8, 2019

FDA approves Ruzurgi for pediatric patients with Lambert-Eaton myasthenic syndrome

May 7, 2019

FDA approves Kadcyla for adjuvant treatment in HER2-positive early breast cancer setting

May 6, 2019

Qternmet XR approved in U.S. for type 2 diabetes

May 3, 2019

FDA approves Tibsovo for newly diagnosed IDH1 mutant AML ineligible for intensive chemotherapy

May 3, 2019

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...